Koike Chihiro, Okudela Koji, Matsumura Mai, Mitsui Hideaki, Suzuki Takehisa, Arai Hiromasa, Kataoka Toshiaki, Ishikawa Yoshihiro, Umeda Shigeaki, Tateishi Yoko, Ohashi Kenichi
Department of Pathology, Yokohama City University, School of Medicine, Yokohama, Japan.
Division of General Thoracic Surgery, Kanagawa Prefectural Cardiovascular and Respiratory Center Hospital, Yokohama, Japan.
Histol Histopathol. 2021 Mar;36(3):305-315. doi: 10.14670/HH-18-294. Epub 2020 Dec 22.
The present study aimed to discern the molecular alterations involved in the progression of EGFR-mutated lung adenocarcinoma (LADC). We previously demonstrated that the micropapillary (mPAP) element is the most important histological factor for assessing malignant grades in LADCs. Therefore, mPAP and other elements were separately collected from three cases of EGFR-mutated LADC using laser capture microdissection and subjected to a comprehensive mRNA expression analysis. We focused on DYRK2 in this study because its level showed a substantial increase in EGFR-mutated LADCs with mPAP. We also immunohistochemically examined 130 tumors for the expression of DYRK2. The results confirmed a strong expression of DYRK2 in EGFR-mutated LADC with mPAP. Fluorescent in situ hybridization (FISH) analyses targeting the DYRK2 locus revealed frequent gene amplification in EGFR-mutated LADC, specifically occurring in the high-grade components, like mPAP. In summary, the results of this study suggest that DYRK2 overexpression through gene amplification is one of the molecular mechanisms responsible for promoting the progression of EGFR-mutated LADC.
本研究旨在识别表皮生长因子受体(EGFR)突变的肺腺癌(LADC)进展过程中涉及的分子改变。我们之前证明,微乳头(mPAP)成分是评估LADC恶性程度的最重要组织学因素。因此,使用激光捕获显微切割技术从3例EGFR突变的LADC病例中分别收集mPAP和其他成分,并进行全面的mRNA表达分析。在本研究中,我们重点关注双特异性酪氨酸磷酸化调节激酶2(DYRK2),因为在伴有mPAP的EGFR突变LADC中其水平显著升高。我们还通过免疫组化检测了130例肿瘤中DYRK2的表达。结果证实,DYRK2在伴有mPAP的EGFR突变LADC中呈强表达。针对DYRK2基因座的荧光原位杂交(FISH)分析显示,EGFR突变的LADC中频繁出现基因扩增,特别是在高级别成分(如mPAP)中。总之,本研究结果表明,通过基因扩增导致的DYRK2过表达是促进EGFR突变LADC进展的分子机制之一。